Cryoport Reports Second Quarter 2026 Financial Results

EarningsPositive

AI Analysis

Summary

Cryoport reported Q2 2026 financial results with 8% year-over-year revenue growth to $49.0 million, driven by 15% growth in Life Sciences Services and 25% growth in BioStorage/BioServices. The company supports 779 global clinical trials and 22 commercially approved cell and gene therapies.

Financial Highlights

Revenue

$49.0 million

Importance:4/10

Sentiment:

0.40

earningsQ2 2026revenue growthcell and gene therapyclinical trials

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Pharma on August 6, 2026 8:05 PM

Read Original